The pharmaceutical company said first-quarter earnings were supported by strong demand for its weight-loss medicines, prompting a higher full-year sales forecast.
Eli Lilly raised its full-year sales outlook after reporting first-quarter earnings that benefited from demand for its weight-loss drugs. The update points to continued commercial strength in the obesity drug market, where prescription demand has become a major driver of revenue growth for large drugmakers.